Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
Nieuwe ASAS-EULAR-richtlijn en de implicaties voor dagelijkse praktijk
nov 2022 | Spondyloartritis